Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1604 - Impact of a cancer care coordination program based on health information technologies for patients treated by oral anticancer therapy: The CAPRI randomized trial


10 Sep 2017


Poster display session


Supportive Care and Symptom Management


Marie Ferrua


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


M. Ferrua1, M. Di Palma1, F. Lemare2, A. Fourcade1, B. Lalloue1, F. Daumas - Yatim3, M. Guillet - Lacaze1, E. Minvielle1

Author affiliations

  • 1 Research Department, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2 Pharmacy Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Ea 7348 Management Des Organisations De Santé, EHESP, 35043 - Rennes/FR


Abstract 1604


The emergence of oral delivery in cancer therapeutics results in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treatment delivery to the patient. There is a significant interest in cancer care coordination programs, especially those combining Nurse Navigators (NN) and the use of new technologies. However, the potential impact of these combined strategies is limited by a lack of rigorous evidence.

Trial design

A monocentric randomized trial (1,000 patients, 1:1) is designed to assess the impact of a cancer care coordination program namely CAPRI. This program is based on two NN and a web application. NN ensure remote patient monitoring, via phone calls and email. They also provide a link between hospital professionals, patients and primary care professionals (GP, private nurse, pharmacist, etc.) by giving them access to the web application with the patient’s authorization. Patients can enter data related to their health. Alerts are sent to the NN in case of abnormal data. NN evaluate the alert level on the basis of algorithms and determine the necessary action. The study will evaluate CAPRI’s efficacy in comparison with regular care during a 6-month period for adult patients with metastatic cancer. Hypothesis is that with a closer monitoring of the patient, the management of toxicities is more efficient and results in fewer dose adjustments of oral cancer therapeutics and avoids unnecessary hospital visits. The primary research aim is to assess the impact of the CAPRI program on treatment delivery for cancer patients who started oral cancer therapy, as measured by Relative Dose Intensity. The trial involves several secondary outcomes: patient adherence, tumor response, survival, toxicities, patient quality of life and patient experience. An economic evaluation adopting a societal perspective will be conducted, in order to estimate the use of healthcare resources. A parallel process evaluation will be conducted to describe the implementation of the CAPRI program. Of the 1,000 patients to be recruited, 109 patients are currently enrolled since November 2016.

Clinical trial identification


Legal entity responsible for the study

Gustave Roussy


National Research French Agency, Philanthropia Lombard Odier Foundation, Astrazeneca, Novartis


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.